You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Fibroblast growth factor receptors (FGFR) Inhibitor

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation
  • Gilbert, Arizona
  • +115 more
Oct 17, 2022

Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer Trial in Buffalo (dovitinib lactate,

Completed
  • Adenocarcinoma of the Pancreas
  • +3 more
  • dovitinib lactate
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022

Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))

Terminated
  • Solid Tumours
  • Debio1347 (CH5183284)
  • Boston, Massachusetts
  • +7 more
Sep 8, 2020

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

Not yet recruiting
  • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
  • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

Achondroplasia Trial in Worldwide (Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg)

Recruiting
  • Achondroplasia
  • Infigratinib 0.016 mg/kg
  • +3 more
  • Oakland, California
  • +17 more
Apr 5, 2022

Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

Not yet recruiting
  • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Apr 16, 2023

Advanced and Metastatic Urothelial Cancer Trial in France, Spain, United States (futibatinib and pembrolizumab)

Recruiting
  • Advanced and Metastatic Urothelial Cancer
  • futibatinib and pembrolizumab
  • San Francisco, California
  • +17 more
Oct 25, 2022

Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Mucosal Melanoma
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Sep 15, 2022

Melanoma Trial in Xi'an (Recombinant human interferon a1b, Toripalimab, Anlotinib HCl)

Not yet recruiting
  • Melanoma
  • Recombinant human interferon α1b
  • +2 more
  • Xi'an, Shaanxi, China
    Air Force Military Medical University/ Fourth Military Medical U
Sep 13, 2022

Urothelial Cancer Trial in Worldwide (Erdafitinib, Vinflunine, Docetaxel)

Recruiting
  • Urothelial Cancer
  • Anchorage, Alaska
  • +414 more
Jul 14, 2022

Immunotherapy in Upper Tract Urothelial Carcinoma

Not yet recruiting
  • Urothelial Carcinoma
  • Evaluation of anti-PD-(L)1 immunotherapy efficacy
  • (no location specified)
Oct 27, 2023

Hormone Refractory Prostate Cancer Trial in Seoul (TKI258)

Completed
  • Hormone Refractory Prostate Cancer
  • Seoul, Chongro-ku, Korea, Republic of
  • +1 more
Feb 16, 2021

Renal Cell Carcinoma Trial in Iowa City (Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy)

Recruiting
  • Renal Cell Carcinoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
May 4, 2022

Urinary Bladder Tumors Trial in Worldwide (Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C))

Recruiting
  • Urinary Bladder Neoplasms
  • Tucson, Arizona
  • +178 more
Mar 24, 2022

Breast Cancer Stage II Trial in Xi'an (Anlotinib)

Recruiting
  • Breast Cancer Stage II
  • Xi'an, Shannxi Province, China
    Xijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022

Melanoma Stage III Trial in North Sydney (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma Stage III
  • North Sydney, New South Wales, Australia
    Melanoma Institute Australia
Oct 26, 2022

Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal

Recruiting
  • Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
  • +4 more
  • Chicago, Illinois
    Northwestern University
Apr 30, 2021

Carcinoma, Transitional Cell Trial in Worldwide (Rogaratinib (BAY1163877), Chemotherapy)

Completed
Has Results
  • Carcinoma, Transitional Cell
  • Anchorage, Alaska
  • +160 more
Feb 11, 2022

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))

Completed
  • Carcinoma, Hepatocellular
  • JNJ-42756493 (erdafitinib)
  • Changchun, China
  • +9 more
Feb 17, 2020

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Ronvatinib + sindillimab, radiofrequency ablation)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Ronvatinib + sindillimab
  • radiofrequency ablation
  • Guangzhou, Guangdong, China
    Third Affiliated Hospital, Sun Yat-Sen University
Apr 5, 2023

Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma Trial in Spain (Cabozantinib 40 mg)

Recruiting
  • Neuroendocrine Tumor
  • +4 more
  • Cabozantinib 40 mg
  • Badalona, Barcelona, Spain
  • +14 more
Feb 15, 2022

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification Trial in Canada, United States (Docetaxel, FGFR

Completed
Has Results
  • FGFR1 Gene Amplification
  • +7 more
  • Birmingham, Alabama
  • +1083 more
May 25, 2021

Hepatocellular Carcinoma Trial in Houston (Lenvatinib, Transcatheter Arterial Chemoembolization)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Houston, Texas
    Houston Methodist Research Institute
Dec 10, 2021